Recurrent Glioblastoma Multiforme (GBM) Treatment Market Report

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 01, 2022
  • PAGES：141
  • REPORT CODE：GMM783620
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Recurrent Glioblastoma Multiforme (GBM) Treatment market report explains the definition, types, applications, major countries, and major players of the Recurrent Glioblastoma Multiforme (GBM) Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Vascular Biogeneics

    • GlaxoSmithKline

    • AngioChem

    • Pfizer

    • Merck

    • Astrazeneca

    • Roche

    By Type:

    • Oral Medications

    • Temozolomide

    • Radiosensitizers

    • Nitrosoureas Drugs

    • Radiation Therapy

    • Chemotherapy

    By End-User:

    • Hospitals

    • Clinics

    • Ambulatory Surgical Centers

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Outlook to 2028- Original Forecasts

    • 2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market- Recent Developments

    • 6.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market News and Developments

    • 6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Deals Landscape

    7 Recurrent Glioblastoma Multiforme (GBM) Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Raw Materials

    • 7.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Price Trend of Key Raw Materials

    • 7.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Suppliers of Raw Materials

    • 7.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Rate of Raw Materials

    • 7.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Cost Structure Analysis

      • 7.5.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Raw Materials Analysis

      • 7.5.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Labor Cost Analysis

      • 7.5.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Manufacturing Expenses Analysis

    8 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Medications Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Temozolomide Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Radiosensitizers Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Nitrosoureas Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Radiation Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Recurrent Glioblastoma Multiforme (GBM) Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.2.2 Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.2 UK Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.3 Spain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.5 France Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.6 Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.8 Finland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.9 Norway Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.11 Poland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.12 Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.2 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.3 India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.3 Chile Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.6 Peru Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.6.3 Oman Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    11 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Competitive Analysis

    • 11.1 Vascular Biogeneics

      • 11.1.1 Vascular Biogeneics Company Details

      • 11.1.2 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.1.4 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 GlaxoSmithKline

      • 11.2.1 GlaxoSmithKline Company Details

      • 11.2.2 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.2.4 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 AngioChem

      • 11.3.1 AngioChem Company Details

      • 11.3.2 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.3.4 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Pfizer

      • 11.4.1 Pfizer Company Details

      • 11.4.2 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.4.4 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Merck

      • 11.5.1 Merck Company Details

      • 11.5.2 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.5.4 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Astrazeneca

      • 11.6.1 Astrazeneca Company Details

      • 11.6.2 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.6.4 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Roche

      • 11.7.1 Roche Company Details

      • 11.7.2 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

      • 11.7.4 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Oral Medications Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Radiosensitizers Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Nitrosoureas Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.6 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Recurrent Glioblastoma Multiforme (GBM) Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Recurrent Glioblastoma Multiforme (GBM) Treatment

    • Figure of Recurrent Glioblastoma Multiforme (GBM) Treatment Picture

    • Table Global Recurrent Glioblastoma Multiforme (GBM) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Recurrent Glioblastoma Multiforme (GBM) Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Oral Medications Consumption and Growth Rate (2017-2022)

    • Figure Global Temozolomide Consumption and Growth Rate (2017-2022)

    • Figure Global Radiosensitizers Consumption and Growth Rate (2017-2022)

    • Figure Global Nitrosoureas Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Table North America Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table Vascular Biogeneics Company Details

    • Table Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Table GlaxoSmithKline Company Details

    • Table GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Table AngioChem Company Details

    • Table AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Table Merck Company Details

    • Table Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Table Astrazeneca Company Details

    • Table Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Table Roche Company Details

    • Table Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Main Business and Markets Served

    • Table Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product Portfolio

    • Figure Global Oral Medications Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiosensitizers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Nitrosoureas Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US